Long-acting reversible contraception for adolescents

Current Opinion in Obstetrics and Gynecology

Volumn 24, Issue 5, 2012, Pages 293-298

  McNicholas, Colleen ^a   Peipert, Jeffrey F ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

adolescent contraception; intrauterine device; long acting reversible contraception; subdermal implant; teen pregnancy

Indexed keywords

CONTRACEPTIVE AGENT; ETONOGESTREL; LEVONORGESTREL; LONG ACTING DRUG; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT;

ADOLESCENT PREGNANCY; DEVICE SAFETY; DRUG IMPLANT; DRUG TREATMENT FAILURE; FEMALE FERTILITY; HORMONAL CONTRACEPTION; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; PATIENT SATISFACTION; PRIORITY JOURNAL; REVIEW; TRANSDERMAL PATCH; TREATMENT CONTRAINDICATION; VAGINA RING;

ADOLESCENT; CONTRACEPTIVE AGENTS, FEMALE; DRUG IMPLANTS; FEMALE; HUMANS; INTRAUTERINE DEVICES; PREGNANCY; PREGNANCY IN ADOLESCENCE; PREGNANCY, UNWANTED; UNITED STATES;

EID: 84866370582     PISSN: 1040872X     EISSN: 1473656X     Source Type: Journal    
DOI: 10.1097/GCO.0b013e32835686d5     Document Type: Review

References (45)

1. Finer LB, Zolna MR. Unintended pregnancy in the United States: incidence and disparities, 2006. Contraception 2011; 84:478-485.
2. Kost K HSACL. US Teenage Pregnancies, Births and, Abortions: National and State Trends and Trends by Race and Ethnicity, http://www.guttmacher. org/pubs/USTPtrends.pdf. [Accessed 31 January 2012]
3. Santelli JS, Lindberg LD, Finer LB, Singh S. Explaining recent declines in adolescent pregnancy in the United States: the contribution of abstinence and improved contraceptive use. Am J public health 2007; 97:150-156. (Pubitemid 46067697)
4. Santelli J, Sandfort T, Orr M. Transnational comparisons of adolescent contraceptive use: what can we learn from these comparisons? Arch Pediatr Adolesc Med 2008; 162:92-94.
5. Darroch JE, Singh S, Frost JJ. Differences in teenage pregnancy rates among five developed countries: the roles of sexual activity and contraceptive use. Family planning perspectives 2001; 33:244-250; 281.
6. Martinez G, Copen CE, Abma JC. Teenagers in the United States: sexual activity, contraceptive use, and childbearing, 2006-2010 national survey of family growth. Vital and health statistics. Series 23, Data from the National Survey of Family Growth 2011; 31:1-35.
7. Mosher WD, Chandra A, Jones J. Sexual behavior and selected health measures: men and women 15-44 years of age, United States, 2002. Adv Data 2005; 362:1-55.
8. Trussell J. Contraceptive efficacy. In: Hatcher RA TJ, Nelson AL, Cates W, Stewart FH, Kowal D, editors. Contraceptive technology. 19th revised ed. New York: Ardent; 2007. p. 759.
9. Winner B, Peipert JF, Zhao Q, et al. Effectiveness of long-acting reversible contraception. N Engl J Med 2012; 366:1998-2007.
10. Centers for Disease Control and Prevention. US Medical eligibility criteria for contraceptive use, http://www.cdc.gov/mmwr/pdf/rr/rr59e0528. pdf aftWHOMecfcute. [Accessed 3 May 2012]
11. Nilsson CG, Haukkamaa M, Vierola H, Luukkainen T. Tissue concentrations of levonorgestrel in women using a levonorgestrel-releasing IUD. Clin Endocrinol 1982; 17:529-536. (Pubitemid 12006959)
12. Hatcher RA TJ, Nelson A, Cates W. Contraceptive technology. 19 ed: Ardent Media; 2007.
13. Andersson JK, Rybo G. Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia. Br J Obstetr Gynaecol 1990; 97:690-694. (Pubitemid 20263115)
14. Baldaszti E, Wimmer-Puchinger B, Loschke K. Acceptability of the long-term contraceptive levonorgestrel-releasing intrauterine system (Mirena): a 3-year follow-up study. Contraception 2003; 67:87-91. (Pubitemid 36174007)
15. Hidalgo M, Bahamondes L, Perrotti M, et al. Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years. Contraception 2002; 65:129-132. (Pubitemid 34258502)
16. Alvarez F, Brache V, Fernandez E, et al. New insights on the mode of action of intrauterine contraceptive devices in women. Fertil steril 1988; 49:768-773.
17. Sivin I, Stern J, Diaz S, et al. Rates and outcomes of planned pregnancy after use of Norplant capsules, Norplant II rods, or levonorgestrel-releasing or copper TCu 380Ag intrauterine contraceptive devices. Am J Obstetr Gynecol 1992; 166:1208-1213.
18. Vessey MP, Lawless M, McPherson K, Yeates D. Fertility after stopping use of intrauterine contraceptive device. Br Med J (Clin Res Ed) 1983; 286:106. (Pubitemid 13147576)
19. Trussell J, Lalla AM, Doan QV, et al. Cost effectiveness of contraceptives in the United States. Contraception 2009; 79:5-14.
20. Hubacher D, Grimes DA. Noncontraceptive health benefits of intrauterine devices: a systematic review. Obstet Gynecol Surv 2002; 57:120-128. (Pubitemid 34132150)
21. Castellsague X, Diaz M, Vaccarella S, et al. Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: a pooled analysis of 26 epidemiological studies. Lancet Oncol 2011; 12:1023-1031.
22. Benshushan A, Paltiel O, Rojansky N, et al. IUD use and the risk of endometrial cancer. Eur J Obstet Gynecol Reprod Biol 2002; 105:166-169.
23. Orbo A, Arnes M, Hancke C, et al. Treatment results of endometrial hyperplasia after prospective D-score classification: a follow-up study comparing effect of LNG-IUD and oral progestins versus observation only. Gynecol Oncol 2008; 111:68-73.
24. Kiriwat O, Patanayindee A, Koetsawang S, et al. A 4-year pilot study on the efficacy and safety of Implanon, a single-rod hormonal contraceptive implant, in healthy women in Thailand. Eur J Contracept Reprod Healthcare 1998; 3:85-91. (Pubitemid 128690533)
25. Affandi B, Korver T, Geurts TB, Coelingh Bennink HJ. A pilot efficacy study with a single-rod contraceptive implant (Implanon) in 200 Indonesian women treated for or 4 years. Contraception 1999; 59:167-174 (Pubitemid 29277546)
26. Mestad R, Secura G, Allsworth JE, et al. Acceptance of long-acting reversible contraceptive methods by adolescent participants in the Contraceptive CHOICE Project. Contraception 2011; 84:493-498.
27. Funk S, Miller MM, Mishell DR Jr, et al. Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel. Contraception 2005; 71:319-326. (Pubitemid 40602307)
28. Weisberg E, Hickey M, Palmer D, et al. A randomized controlled trial of treatment options for troublesome uterine bleeding in Implanon users. Hum Reprod 2009; 24:1852-1861.
29. ACOG Committee Opinion No. 392, December 2007. Intrauterine device and adolescents. Obstet Gynecol 2007; 110:1493-1495.
30. Farley TM, Rosenberg MJ, Rowe PJ, et al. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet 1992; 339:785-788.
31. Rasheed SM, Abdelmonem AM. Complications among adolescents using copper intrauterine contraceptive devices. Int J Gynaecol Obstet 2011; 115:269-272.
32. Teal SB, Sheeder J. IUD use in adolescent mothers: retention, failure and reasons for discontinuation. Contraception 2012; 85:270-274.
33. Madden T MC, Securra G, Alsworth J, et al. Rates of continuation and expulsion of intrauterine contraception at 12 months in nulliparous and adolescent women. Contraception. 2010; 82:187-188.
34. Brockmeyer A, Kishen M, Webb A. Experience of IUD/IUS insertions and clinical performance in nulliparous women-a pilot study. Eur J Contracept Reprod Healthcare 2008; 13:248-254.
35. Blanc AK, Tsui AO, Croft TN, Trevitt JL. Patterns and trends in adolescents' contraceptive use and discontinuation in developing countries and comparisons with adult women. Int Perspect Sex Reprod Health 2009; 35:63-71.
36. Deans EI, Grimes DA. Intrauterine devices for adolescents: a systematic review. Contraception 2009; 79:418-423.
37. Peipert JF, Zhao Q, Allsworth JE, et al. Continuation and satisfaction of reversible contraception. Obstet Gynecol 2011; 117:1105-1113.
38. Update to CDC's US Medical Eligibility Criteria for Contraceptive Use, 2010: revised recommendations for the use of contraceptive methods during the postpartum period. MMWR 2011; 60:878-883.
39. ACOG Practice Bulletin No. 121: Long-acting reversible contraception: Implants and intrauterine devices. Obstet Gynecol 2011; 118:184-196.
40. Allen RH, Bartz D, Grimes DA, et al. Interventions for pain with intrauterine device insertion. Cochrane Database Syst Rev. 2009:CD007373.
41. Massey SE, Varady JC, HenzlMR. Pain relief with naproxen following insertion of an intrauterine device. J Reprod Med 1974; 13:226-231.
42. Dijkhuizen K, Dekkers OM, Holleboom CA, et al. Vaginal misoprostol prior to insertion of an intrauterine device: an RCT. Hum Reprod 2011; 26:323-329.
43. Saav I, Aronsson A, Marions L, et al. Cervical priming with sublingual misoprostol prior to insertion of an intrauterine device in nulliparous women: a randomized controlled trial. Hum Reprod 2007; 22:2647-2652. (Pubitemid 47434207)
44. Behringer T, Reeves MF, Rossiter B, et al. Duration of use of a levonorgestrel IUS amongst nulliparous and adolescent women. Contraception 2011; 84:e5-e10.
45. Cleland K, Peipert JF, Westhoff C, et al. Family planning as a cost-saving preventive health service. N Engl J Med 2011; 364:e37.